• 1
    Tashiro H, Blazes MS, Wu R et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997; 57: 393540.
  • 2
    Mizuuchi H, Nasim S, Kudo R, Silverberg SG, Greenhouse S, Garrett CT. Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. Cancer Res 1992; 52: 277781.
  • 3
    Imamura T, Arima T, Kato H, Miyamoto S, Sasazuki T, Wake N. Chromosomal deletions and K-ras gene mutations in human endometrial carcinomas. Int J Cancer 1992; 51: 4752.
  • 4
    Enomoto T, Fujita M, Inoue M et al. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res 1993; 53: 18838.
  • 5
    Kanaya T, Kyo S, Sakaguchi J et al. Association of mismatch repair deficiency with PTEN frameshift mutations in endometrial cancers and the precursors in a Japanese population. Am J Clin Pathol 2005; 124: 18.
  • 6
    Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 42430.
  • 7
    Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1999; 80: 17985.
  • 8
    Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410: 3740.
  • 9
    Pearson G, Robinson F, Beers Gibson T et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001; 22: 15383.
  • 10
    Kyo S, Nakamura M, Kiyono T et al. Successful immortalization of endometrial glandular cells with normal structural and functional characteristics. Am J Pathol 2003; 163: 225969.
  • 11
    Mizumoto Y, Kyo S, Ohno S et al. Creation of tumorigenic human endometrial epithelial cells with intact chromosomes by introducing defined genetic elements. Oncogene 2006; 25: 567382.
  • 12
    Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6: 18492.
  • 13
    Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow MA. Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 1998; 92: 25363.
  • 14
    Wakioka T, Sasaki A, Kato R et al. Spred is a Sprouty-related suppressor of Ras signalling. Nature 2001; 412: 64751.
  • 15
    Furthauer M, Lin W, Ang SL, Thisse B, Thisse C. Sef is a feedback-induced antagonist of Ras/MAPK-mediated FGF signalling. Nat Cell Biol 2002; 4: 1704.
  • 16
    Tsang M, Friesel R, Kudoh T, Dawid IB. Identification of Sef, a novel modulator of FGF signalling. Nat Cell Biol 2002; 4: 1659.
  • 17
    Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 94954.
  • 18
    Mutch DG, Powell MA, Mallon MA, Goodfellow PJ. RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers. Am J Obstet Gynecol 2004; 190: 93542.
  • 19
    Svensson S, Jirstrom K, Ryden L et al. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 2005; 24: 43709.
  • 20
    Pappa KI, Choleza M, Markaki S et al. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Gynecol Oncol 2006; 100: 596600.
  • 21
    Feng YZ, Shiozawa T, Miyamoto T et al. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression. Clin Cancer Res 2005; 11: 61338.
  • 22
    Handra-Luca A, Bilal H, Bertrand JC, Fouret P. Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation. Am J Pathol 2003; 163: 95767.
  • 23
    Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F, Eppenberger U. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 2000; 89: 3848.
  • 24
    Milde-Langosch K, Bamberger AM, Rieck G et al. Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer 2005; 92: 220615.
  • 25
    Givant-Horwitz V, Davidson B, Lazarovici P et al. Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol 2003; 91: 16072.